Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 13/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.49 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425278 | 0.91 | WNT3A (0.59) | WNT3AMEN1KMT2ACACNA1HSLC6A2 | |
| SCHEMBL3423501 | 0.85 | CACNA1H (0.49) | WNT3AMEN1KMT2ACACNA1HCACNA1G | |
| SCHEMBL4296226 | 0.84 | MAOB (0.63) | WNT3AMEN1KMT2ACACNA1HCACNA1G | |
| SCHEMBL3400958 | 0.83 | WNT3A (0.56) | WNT3AKMT2ACACNA1HCACNA1GCACNA1I | |
| SCHEMBL3428240 | 0.80 | CACNA1H (0.53) | WNT3ACACNA1HCACNA1GCACNA1IMAOB | |
| SCHEMBL3423491 | 0.80 | CACNA1H (0.51) | WNT3AMEN1KMT2ACACNA1HCACNA1G | |
| SCHEMBL3430922 | 0.80 | WNT3A (0.60) | WNT3AMAOB | |
| SCHEMBL3428296 | 0.80 | CACNA1H (0.50) | WNT3ACACNA1HCACNA1GCACNA1IMAOB | |
| SCHEMBL3401458 | 0.80 | CACNA1H (0.50) | WNT3AMEN1KMT2ACACNA1HCACNA1G | |
| SCHEMBL21286264 | 0.80 | WNT3A (0.78) | WNT3AMEN1KMT2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250162-B1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-19 | — | — | EP | claimed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | claimed |
| CN-101990537-A | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LAB | 2011-03-23 | — | — | CN | claimed |
| EP-2250162-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | claimed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | claimed |
| WO-2009100294-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | WO | claimed |
| EP-2250162-B1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| CN-101990537-A | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LAB | 2011-03-23 | — | — | CN | disclosed |
| EP-2250162-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009100294-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA2, CHRNA4, CHRNA5 | WNT3A 4288/4885MEN1 4147/4885KMT2A 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.